Ligand competition assays indicate allosterism and insufficiency of the ternary complex model

References

• De Lean A, Stadel JM, Lefkowitz RJ. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Bio Chem. 1980;255:7108–7117.
   PubMed Web of Science ®Google Scholar
• Seifert R, Wenzel-Seifert K, Gether U, Kobilka B. Functional difference between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther. 2001;297:1218–1226.
   PubMed Web of Science ®Google Scholar
• Vittori S, Lorenzen A, Stannek C, et al. N-Cycloalkyl Derivatives of adenosine and 1-Deazaadenosine as agonists and partial agonists of the A1 adenosine receptor. J Med Chem. 2000;43:250–260.
   PubMed Web of Science ®Google Scholar
• Kent R, De Lean A, Lefkowitz R. A Quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low affinity states of the receptor by computer modeling of ligand binding data. Mol Pharmacol. 1980;17:14–23.
   PubMed Web of Science ®Google Scholar
• Birdsall N, Burgen A, Hulme E. The binding of agonists to brain muscharinic receptors. Mol Pharmacol. 1978;14:723–736.
   PubMed Web of Science ®Google Scholar
• Lefkowitz R, Mullikin D, Caron M. Regulation of p-adrenergic beceptors by guanyl-5’-yl imidophosphate and other purine nucleotides. J Biol Chem. 1976;251:4686–4692.
   PubMed Web of Science ®Google Scholar
• Christopoulos A, Grant M, El-Fakahany E. Transducer abstraction; a novel approach to the detection of partial agonist efficacy in radioligand binding studies. J Pharmacol Toxicol Methods. 2000;43:55–67.
   Web of Science ®Google Scholar
• Tolkovsky A, Levitzki A. Mode of coupling between the beta-adrenergic receptor and adenylate cyclase in turkey erythrocytes. Biochemistry. 1978;17:3795–3810.
   PubMed Web of Science ®Google Scholar
• Boeyaems J, Dumont J. Quantitative analysis of the binding of ligands to their receptors. J Cyclic Nucleotide Res. 1975;1:123–142.
   Google Scholar
• Sibley D, Creese I. Interaction of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol. 1982;23:585–593.
   Web of Science ®Google Scholar
• Ehlert F. The relationship between muscarinic receptor occupancy and adenylate cycalse inhibition in the rabbit myocardium. Mol Pharmacol. 1985;28:410–421.
   PubMed Web of Science ®Google Scholar
• Gardner B, Strange P Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol. 1998;124:978–984.
   PubMed Web of Science ®Google Scholar
• Lahti R, Figur L, Piercey M, Ruppel P, Evans D. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-bindin-coupled receptor: utilization of receptor state binding affinities. Mol Pharmacol. 1992;42:432–438.
   PubMed Web of Science ®Google Scholar
• Malmberg A, Mohell N, Hook B, Johansson A, Hacksell U, Nordvall G. Interactions of ligands with active and inactive conformations of the dopamine D2 receptor. Eur J Pharmacol. 1998;346:299–307.
   PubMed Web of Science ®Google Scholar
• Watson J, Collin L, Ho M, et al. 5-HT^ receptor agonist-antagonist binding affinity differences as a measure of intrinsic activity in recombinant and native tissue systems. Br J Pharmacol. 2000;130:1108–1114.
   PubMed Web of Science ®Google Scholar
• Payne S, Johansson A, Strange P. Mechanisms of ligand binding and efficacy at the human D2(shoit) dopamine receptor. J Neurochem. 2002;82:1106–1117.
   Web of Science ®Google Scholar
• Egan C, Grinde E, Dupre A, et al. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT2a and 5-HT2c receptors. Synapse. 2000;35:144–150. 2A 2C
   Web of Science ®Google Scholar
• Fitzgerald L, Conklin D, Krause C, et al. High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5- HT2a and 5-HT2c receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999;72:2127–2134.
   Web of Science ®Google Scholar
• Newman-Tancredi A, Verriele L, Touzard M, Millan M. Efficacy of antipsychotic agents at human 5-HT1A receptors determined by [3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur J Pharmacol 2001;428:177–184.
   Google Scholar
• Hoffman B, Michel T, Brenneman T, Lefkowitz R. Interactions of agonists with platelet α2-adrenergic receptors. Endocrinology 1982;110:926–932. 2
   Web of Science ®Google Scholar
• Samama P, Cotecchia S, Costa T, Lefkowitz R. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 1993;268:4625–4636.
   Web of Science ®Google Scholar
• Van Schaick E, Mathôt R, Gubbens-Stibbe J, et al. 8-Alkylamino- substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo. J Pharmacol Exp Ther. 1997;283:800–808.
   PubMed Web of Science ®Google Scholar
• Roelen H, Veldman N, Spek A, Kunzel J, Mathot R, IJzerman A. N6, C8-disubstituted adenosine derivatives as partial agonists for adenosine A1 receptors. J Med Chem. 1996;39:1463–1471.
   PubMed Web of Science ®Google Scholar
• Egan C, Grinde E, Dupre A, et al. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors. Synapse. 2000;35:144–150.
   Web of Science ®Google Scholar
• Assie MB, Cosi C, Wouter K. Correlation between low/high affinity ratios for 5-HT1A receptors and intrinsic activity. Eur J Pharmacol. 1999;386:97–103A.
   Web of Science ®Google Scholar
• Van der Wenden EM, Hartog-Witte HR, Roelen HC, et al. 8-substituted adenosine and theophylline-7-riboside analogues as potential partial agonists for the adenosine A1 receptor. Eur J Pharmacol. 1995;290:189–199.
   PubMed Web of Science ®Google Scholar
• Roberts D, Lin H, Strange P. Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol 2004;67:1657–1665.
   Web of Science ®Google Scholar
• Alder J, Hacksell U, Strange P. Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino) tetralins at the 5-HT1A serotonin receptor. Br J Pharmacol. 2003;138:1129–1139.
   Web of Science ®Google Scholar
• Kenakin T. Agonist-specific receptor conformations. Trends Pharmacol Sci. 1997;18:416–417.
   PubMed Web of Science ®Google Scholar
• Hosohata Y, Varga E, Stropova D, et al. Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for activation. Life Sci. 2001;68:2233–2242.
   Web of Science ®Google Scholar
• Weiss J, Morgan P, Lutz M, Kenakin T. The cubic ternary complex model I. Model description. J Theor Biol. 1996;178:151–167.
   Web of Science ®Google Scholar
• Hall DA. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 2000;58:1412–1423.
   PubMed Web of Science ®Google Scholar
• Strudwick N, Bhogal N, Evans N, Blaney F, Findlay J. Evidence to support a spectrum of active states for the glucagon receptor. Biochem Soc Trans. 2004;32:1037–1039.
   Web of Science ®Google Scholar
• Roberts D, Lin H, Strange P. Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors. Biochem Pharmacol. 2004;67:1657–1665.
   Web of Science ®Google Scholar
• Krumins A, Lapeyre JN, Clark RB, Barber R. Evidence for the shuttle model for gp activation of adenylyl cyclase. Biochem Pharmacol. 1997;54:43–59.
   Web of Science ®Google Scholar
• Lee E, Linder ME, Gilman AG. Expression of a subunits in Escherichia Coli. Methods Enzymol. 1994;237:146–164.
   PubMed Web of Science ®Google Scholar
• Iniguez-Lluhi JA, Simon MI, Robishaw JD, Gilman AG. G protein beta gamma subunits synthesized in Sf9 cells. Functional characterization and the significance of prenylation of gamma. J Biol Chem. 1992;267:23409–23417.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
   PubMed Web of Science ®Google Scholar
• Armour S, Foord S, Kenakin T, Chen WJ. Pharmacological characterization of receptor-activity-modifyins (RAMPs) and the human calcitonin receptor. J Pharmacol Toxicol. 1999;42:217–224.
   PubMed Web of Science ®Google Scholar
• Lidow MS, Roberts A, Zhang L, Koh PO, Lezcano N, Bergson C. Receptor crosstalk protein, calcyon, regulates affinity state of dopamine D1 receptors. Eur J Pharmacol. 2001;427:187–193.
   Web of Science ®Google Scholar
• Christopoulos A, Kenakin T. G-protein-coupled receptor allosterism and complexing. Pharmacol Rev. 2002;54:323–374.
   PubMed Web of Science ®Google Scholar
• Nanoff C, Waldhoer M, Roka F, Freissmuth M. G protein coupling of the rat A1-adenosine receptor-partial purification of a protein which stabilizes the receptor-G protein association. Neuropharmacol. 1997;36:1211–1219.
   PubMed Web of Science ®Google Scholar
• Lin H, Saisch S, Strange P. Assays for enhanced activity of low efficacy partial agonists at the D2 dopamine receptor. Br J Pharmacol. 2006;149:291–299.
   Web of Science ®Google Scholar
• Galvez T, Urwyler S, Prezeau L, et al. Ca(2+) requirement for high-affinity gamma-aminobutyric acid (GABA) binding at GABA(B) receptors: involvement of serine 269 of the GABA(B)R1 subunit. Mol Pharmacol. 2000;57:419–426.
   Web of Science ®Google Scholar
• May L, Leach K, Sexton P, Christopoulos A. Allosteric modulation of g protein-coupled receptors. Annu Rev Pharmacol Toxicol. 2007;47:41–51.
   Web of Science ®Google Scholar
• Gilchrist A. Modulating G-protein-coupled receptors: from traditional pharmacology to allosterics. Trends Pharmacol Sci. 2007;28:431–437.
   Web of Science ®Google Scholar